SG11201907335UA - Aminotriazolopyridines as kinase inhibitors - Google Patents
Aminotriazolopyridines as kinase inhibitorsInfo
- Publication number
- SG11201907335UA SG11201907335UA SG11201907335UA SG11201907335UA SG11201907335UA SG 11201907335U A SG11201907335U A SG 11201907335UA SG 11201907335U A SG11201907335U A SG 11201907335UA SG 11201907335U A SG11201907335U A SG 11201907335UA SG 11201907335U A SG11201907335U A SG 11201907335UA
- Authority
- SG
- Singapore
- Prior art keywords
- route
- princeton
- myers squibb
- line road
- squibb company
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458144P | 2017-02-13 | 2017-02-13 | |
| PCT/US2018/017755 WO2018148626A1 (en) | 2017-02-13 | 2018-02-12 | Aminotriazolopyridines as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907335UA true SG11201907335UA (en) | 2019-09-27 |
Family
ID=61283335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907335UA SG11201907335UA (en) | 2017-02-13 | 2018-02-12 | Aminotriazolopyridines as kinase inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10913738B2 (ko) |
| EP (1) | EP3580220B1 (ko) |
| JP (1) | JP7097373B2 (ko) |
| KR (1) | KR102549952B1 (ko) |
| CN (1) | CN110520423B (ko) |
| AU (1) | AU2018217488B2 (ko) |
| BR (1) | BR112019016635A2 (ko) |
| CA (1) | CA3053484A1 (ko) |
| CY (1) | CY1124978T1 (ko) |
| DK (1) | DK3580220T3 (ko) |
| EA (1) | EA039808B1 (ko) |
| ES (1) | ES2902676T3 (ko) |
| HR (1) | HRP20212000T1 (ko) |
| HU (1) | HUE057801T2 (ko) |
| IL (1) | IL268614B (ko) |
| LT (1) | LT3580220T (ko) |
| MA (1) | MA47460A (ko) |
| MX (1) | MX2019009555A (ko) |
| PL (1) | PL3580220T3 (ko) |
| PT (1) | PT3580220T (ko) |
| RS (1) | RS62801B1 (ko) |
| SG (1) | SG11201907335UA (ko) |
| SI (1) | SI3580220T1 (ko) |
| WO (1) | WO2018148626A1 (ko) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3580220T1 (sl) * | 2017-02-13 | 2022-01-31 | Bristol-Myers Squibb Company | Aminotriazolopiridini kot kinazni inhibitorji |
| SI3704118T1 (sl) * | 2017-10-30 | 2022-04-29 | Bristol-Myers Squibb Company | Aminoimidazopiridazini kot kinazni inhibitorji |
| EP3743430B1 (en) | 2018-01-26 | 2023-08-02 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| US20210139456A1 (en) * | 2018-07-09 | 2021-05-13 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting nav1.8 |
| KR20210060516A (ko) | 2018-09-13 | 2021-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 인다졸 카르복스아미드 |
| CA3127701C (en) * | 2019-01-25 | 2023-08-15 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
| CN113508109B (zh) * | 2019-03-22 | 2023-02-10 | 劲方医药科技(上海)有限公司 | 取代的杂环酰胺类化合物，其制法与医药上的用途 |
| EP4105216A4 (en) * | 2020-02-13 | 2024-02-28 | Genfleet Therapeutics Shanghai Inc | DIHYDRONAPHTHYRIDINONE COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL USE THEREOF |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| TWI824626B (zh) * | 2021-08-02 | 2023-12-01 | 大陸商勁方醫藥科技(上海)有限公司 | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 |
| CN117460722A (zh) | 2021-08-10 | 2024-01-26 | 艾伯维公司 | 烟酰胺ripk1抑制剂 |
| CN116574053A (zh) * | 2022-06-21 | 2023-08-11 | 中国药科大学 | Ripk1激酶靶点抑制剂及其医药用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050288502A1 (en) | 2004-06-25 | 2005-12-29 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
| US8008481B2 (en) * | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| AU2008328882A1 (en) | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as PI3K inhibitors |
| WO2010007100A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| EP2393813B1 (en) | 2009-02-04 | 2013-07-31 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| BR112015030774A2 (pt) | 2013-06-10 | 2017-07-25 | Bayer Pharma AG | novos compostos para o tratamento de câncer |
| EP3182974A1 (en) * | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| BR112018008765B1 (pt) | 2015-11-05 | 2022-05-24 | Sumitomo Chemical Company, Limited | Composto heterocíclico condensado, composição e método para o controle de um artrópode nocivo |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| JP7190906B2 (ja) | 2017-01-24 | 2022-12-16 | 住友化学株式会社 | 縮合複素環化合物及びそれを含有する組成物 |
| SI3580220T1 (sl) * | 2017-02-13 | 2022-01-31 | Bristol-Myers Squibb Company | Aminotriazolopiridini kot kinazni inhibitorji |
| SI3704118T1 (sl) | 2017-10-30 | 2022-04-29 | Bristol-Myers Squibb Company | Aminoimidazopiridazini kot kinazni inhibitorji |
| EP3743430B1 (en) | 2018-01-26 | 2023-08-02 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
-
2018
- 2018-02-12 SI SI201830511T patent/SI3580220T1/sl unknown
- 2018-02-12 JP JP2019543377A patent/JP7097373B2/ja active Active
- 2018-02-12 US US16/484,604 patent/US10913738B2/en active Active
- 2018-02-12 HU HUE18707498A patent/HUE057801T2/hu unknown
- 2018-02-12 MA MA047460A patent/MA47460A/fr unknown
- 2018-02-12 PT PT187074984T patent/PT3580220T/pt unknown
- 2018-02-12 EA EA201991915A patent/EA039808B1/ru unknown
- 2018-02-12 DK DK18707498.4T patent/DK3580220T3/da active
- 2018-02-12 HR HRP20212000TT patent/HRP20212000T1/hr unknown
- 2018-02-12 WO PCT/US2018/017755 patent/WO2018148626A1/en unknown
- 2018-02-12 CA CA3053484A patent/CA3053484A1/en active Pending
- 2018-02-12 RS RS20220021A patent/RS62801B1/sr unknown
- 2018-02-12 PL PL18707498T patent/PL3580220T3/pl unknown
- 2018-02-12 KR KR1020197026464A patent/KR102549952B1/ko active IP Right Grant
- 2018-02-12 EP EP18707498.4A patent/EP3580220B1/en active Active
- 2018-02-12 ES ES18707498T patent/ES2902676T3/es active Active
- 2018-02-12 MX MX2019009555A patent/MX2019009555A/es unknown
- 2018-02-12 CN CN201880024064.1A patent/CN110520423B/zh active Active
- 2018-02-12 AU AU2018217488A patent/AU2018217488B2/en active Active
- 2018-02-12 SG SG11201907335UA patent/SG11201907335UA/en unknown
- 2018-02-12 BR BR112019016635A patent/BR112019016635A2/pt unknown
- 2018-02-12 LT LTEPPCT/US2018/017755T patent/LT3580220T/lt unknown
-
2019
- 2019-08-09 IL IL268614A patent/IL268614B/en unknown
-
2020
- 2020-12-09 US US17/116,016 patent/US20220315580A1/en active Pending
-
2022
- 2022-01-18 CY CY20221100043T patent/CY1124978T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3580220T3 (da) | 2022-01-10 |
| JP7097373B2 (ja) | 2022-07-07 |
| US20220315580A1 (en) | 2022-10-06 |
| US20190389859A1 (en) | 2019-12-26 |
| KR20190117006A (ko) | 2019-10-15 |
| PL3580220T3 (pl) | 2022-02-07 |
| MA47460A (fr) | 2019-12-18 |
| CN110520423A (zh) | 2019-11-29 |
| SI3580220T1 (sl) | 2022-01-31 |
| IL268614B (en) | 2021-12-01 |
| US10913738B2 (en) | 2021-02-09 |
| AU2018217488B2 (en) | 2021-09-23 |
| IL268614A (en) | 2019-10-31 |
| WO2018148626A1 (en) | 2018-08-16 |
| JP2020507582A (ja) | 2020-03-12 |
| KR102549952B1 (ko) | 2023-06-29 |
| HRP20212000T1 (hr) | 2022-04-01 |
| CN110520423B (zh) | 2022-08-23 |
| BR112019016635A2 (pt) | 2020-04-07 |
| EP3580220A1 (en) | 2019-12-18 |
| CA3053484A1 (en) | 2018-08-16 |
| PT3580220T (pt) | 2022-01-03 |
| AU2018217488A1 (en) | 2019-10-03 |
| CY1124978T1 (el) | 2023-01-05 |
| RS62801B1 (sr) | 2022-02-28 |
| EA039808B1 (ru) | 2022-03-16 |
| EP3580220B1 (en) | 2021-11-17 |
| HUE057801T2 (hu) | 2022-06-28 |
| EA201991915A1 (ru) | 2019-12-30 |
| ES2902676T3 (es) | 2022-03-29 |
| LT3580220T (lt) | 2021-12-27 |
| MX2019009555A (es) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907335UA (en) | Aminotriazolopyridines as kinase inhibitors | |
| SG11201807980QA (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer | |
| SG11201811321TA (en) | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists | |
| SG11201811590RA (en) | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | |
| SG11201805927YA (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201900619XA (en) | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201907216WA (en) | Adjustable flow nozzle system | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201909429VA (en) | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201811251RA (en) | Multi-chamber deposition equipment for solid free form fabrication | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis |